Valanx Biotech & FinaBio introduce ClickCRM for rapid conjugate vaccine development: Klosterneuburg, Austria Thursday, October 31, 2024, 15:00 Hrs [IST] Valanx Biotech, a biotech ...

Just like our memory and reflexes, the ageing of our immune system can not only cause it to forget how to react to certain ...

A classical example is the polysaccharide antigens of pneumococci. Although this bacterium has >90 chemically different polysaccharide forms, most human disease is associated with only 23 variants.

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...

Their enhanced immunogenicity is achieved through the conjugation of polysaccharide antigens to protein carriers. Using synthetic biology, FinaBio and VALANX have created ClickCRM, a product that ...

Decades ago, scientists looking for an alternative to animal testing cloned factor C, the horseshoe crab protein that senses ...

Vaccines can be composed of complex antigen combinations. For example, developing a Streptococcus pneumoniae vaccine involves testing and combining up to 23 different capsule polysaccharides—antigens ...

The MAP technology combines polysaccharide and protein antigens – joined with a biotin-rhizavidin bond – that can stimulate both B cell (antibody) and T cell immune responses with a single shot.